BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tenofovir disoproxil fumarate (Viread) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tenofovir disoproxil fumarate (Viread)\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06511063-8395@assetmemo.bio
DTSTAMP:20261121T010024Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 2 readout est. (NCT06
 511063)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 2.\nStudy: Antiv
 iral Clinical Trial for Long Covid-19\nEstimated primary completion: Novem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tenofovir-d
 isoproxil-fumarate-viread#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06511063
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05403047-8395@assetmemo.bio
DTSTAMP:20261121T010024Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 4 readout est. (NCT05
 403047)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 4\, Chronic Hepa
 titis B.\nStudy: Efficacy of Tenofovir Disoproxil on Mother-to-child Trans
 mission of HBV in Tokombéré\, Cameroon in Pregnant Women\nEstimated prim
 ary completion: August 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tenofovir-disoproxil-fumarate-viread#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05403047
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673965-8395@assetmemo.bio
DTSTAMP:20261121T010024Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 4 readout est. (NCT07
 673965)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 4\, HIV.\nStudy:
  Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial
  of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Liv
 ing With HIV\nEstimated primary completion: 31 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-virea
 d#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 673965
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075146-8395@assetmemo.bio
DTSTAMP:20261121T010024Z
DTSTART;VALUE=DATE:20271205
DTEND;VALUE=DATE:20271206
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 3 readout est. (NCT07
 075146)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 3\, HIV.\nStudy:
  DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HI
 V and Overweight or Obesity\nEstimated primary completion: 5 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tenofovir-disoproxi
 l-fumarate-viread#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07075146
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203132-8395@assetmemo.bio
DTSTAMP:20261121T010024Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 3 readout est. (NCT06
 203132)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 3\, HIV.\nStudy:
  DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment
 -naïve People Living With HIV-1 Infection\nEstimated primary completion: 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tenofov
 ir-disoproxil-fumarate-viread#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06203132
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05652478-8395@assetmemo.bio
DTSTAMP:20261121T010024Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 2 readout est. (NCT05
 652478)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 2.\nStudy: Early
  Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 
 2 Randomized Study\nEstimated primary completion: 31 January 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tenofovir-disoproxil-fumarat
 e-viread#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05652478
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555431-8395@assetmemo.bio
DTSTAMP:20261121T010024Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 2 readout est. (NCT07
 555431)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 2.\nStudy: Dolut
 egravir Versus Dolutegravir in Combination With Tenofovir for the Treatmen
 t of HTLV-1 Infection\nEstimated primary completion: May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-vi
 read#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07555431
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631897-8395@assetmemo.bio
DTSTAMP:20261121T010024Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 4 readout est. (NCT07
 631897)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 4\, HIV.\nStudy:
  Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF)
  and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens\nEstimated primary compl
 etion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ten
 ofovir-disoproxil-fumarate-viread#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07631897
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797231-8395@assetmemo.bio
DTSTAMP:20261121T010024Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 3 readout est. (NCT07
 797231)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 3\, Chronic Hepa
 titis B.\nStudy: Clinical Trial of TQA3605 Tablet in Combination With Nucl
 eos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients Wi
 th Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Ex
 hibit Low Viral Load or Poor Response\nEstimated primary completion: Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tenofovir-
 disoproxil-fumarate-viread#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07797231
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04375800-8395@assetmemo.bio
DTSTAMP:20261121T010024Z
DTSTART;VALUE=DATE:20281112
DTEND;VALUE=DATE:20281113
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 2 readout est. (NCT04
 375800)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 2\, HIV.\nStudy:
  Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children 
 Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)\nEstimated primary comp
 letion: 12 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tenofovir-disoproxil-fumarate-viread#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04375800
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07553767-8395@assetmemo.bio
DTSTAMP:20261121T010024Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 1 readout est. (NCT07
 553767)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 1\, Chronic Hepa
 titis B.\nStudy: Efficacy and Safety of Pegylated Interferon Alpha-2β in 
 Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical R
 esection\nEstimated primary completion: 31 December 2034. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0755
 3767
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
